



BJA
British Journal of Anaesthesia

Surgery and opioids: An expert consensus based best practice guidance (practice advisory) on the perioperative use of opioids in the United Kingdom.

Journal:	<i>British Journal of Anaesthesia</i>
Manuscript ID	BJA-2020-01996-HH1265.R3
Article Type:	Special article
Date Submitted by the Author:	n/a
Complete List of Authors:	Srivastava, Devjit; Raigmore Hospital, Anaesthesia Hill , Susan ; University Hospital of Wales, Vascular Surgery Carty , Suzanne; Taunton and Somerset NHS Foundation Trust, Anaesthetics and Pain Medicine Rockett, Mark; Plymouth Hospitals NHS Trust, Anaesthesia and Pain Medicine Bastable , Ruth ; Royal College of General Practitioners, General practice Knaggs, Roger; University of Nottingham, Faculty of Science Lambert , David G; University of Leicester, University department Cardiovascular sciences, Anaesthesia, Critical Care and Pain Management Levy , Nicholas ; West Suffolk Hospital, Anaesthesia and Perioperative Medicine Hughes , John ; James Cook University Hospital, Pain Management Unit Wilkinson , Paul ; Royal Victoria Infirmary, Anaesthetics
Keywords:	Surgery, Anaesthesia, Perioperative, Opioids, Pain, Guideline, Post operative pain, Opioid crisis

SCHOLARONE™
Manuscripts

Surgery and opioids guideline




Figure 2: Key recommendations.

65x86mm (300 x 300 DPI)




Figure 1:Guideline development process

65x86mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Surgery and opioids: An expert consensus based best practice guidance
(practice advisory) on the perioperative use of opioids in the United Kingdom.

Devjit Srivastava^{1*}, Susan Hill², Suzanne Carty³, Mark Rockett⁴, Ruth Bastable⁵,
Roger Knaggs⁶, David Lambert⁷, Nicholas Levy⁸, John Hughes⁹, Paul Wilkinson¹⁰.

¹Department of Anaesthesia and Pain Medicine, Raigmore Hospital, Inverness,
Scotland, UK.

² Dept Vascular Surgery ,University Hospital Wales, , Cardiff, UK.

³ Taunton and Somerset NHS Foundation Trust, Anaesthetics and Pain Medicine
Taunton, Somerset, UK.

⁴Plymouth Hospitals NHS Trust, Anaesthesia and Pain Medicine, Plymouth, K.

⁵Royal College of General Practitioners, London, UK.

⁶School of Pharmacy, University of Nottingham, University Park, Nottingham, UK.

⁷Department of Cardiovascular Sciences, Division of Anaesthesia Critical Care & Pain
Management, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary,
Leicester, UK.

⁸Anaesthesia and Perioperative Medicine, West Suffolk Hospital, Bury Saint
Edmunds, Suffolk, UK.

⁹James Cook University Hospital, Pain Management Unit, Middlesbrough,
Middlesbrough, UK.

¹⁰ Department of Anaesthesia, Newcastle Pain Management Unit, Royal Victoria Infirmary Queen Victoria Road, Newcastle upon Tyne, Newcastle, UK.

Abbreviated title: Surgery and Opioids. Author for correspondence:

Devjit Srivastava, M.B.B.S, MD, DNB, FRCA, FFPMRCA, MSc

Department of Anaesthesia and Pain Medicine, Raigmore Hospital, Inverness, Scotland, UK Tel +44 (0) 01463 705350 (secy)

e-mail: dev.srivastava@nhs.scot

Please address reprints requests to Dr. Devjit Srivastava¹

Abstract:

There have been significant concerns regarding prescription and misuse of prescription opioids in the peri-operative period. The Faculty of Pain Medicine (FPM at the Royal College of Anaesthesia) has produced this evidence based expert consensus guideline 'Surgery and Opioids' along with the Royal College of Surgery, Royal College of Psychiatry, Royal College of Nursing and the British Pain Society. This expert consensus practice advisory reproduces the FPM guidance.

Perioperative stewardship of opioids starts with judicious opioid prescribing in primary and secondary care. Prior to surgery, it is important to assess risk factors for continued opioid use after surgery and identify those with chronic pain prior to surgery, some of whom may be taking opioids. A multidisciplinary perioperative care plan that includes a prehabilitation strategy, intra- and post-operative care needs to be formulated. This may need the input of a pain specialist. Emphasis is placed on optimum management of pain pre-, intra- and post-operatively. The use of immediate release opioids is preferred in the immediate post-operative period. Attention to ensuring a smooth care

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

transition and communication from secondary to primary care for those taking opioids is highlighted. For opioid naïve patients (patients not taking opioids prior to surgery), no more than seven days opioid prescription is recommended. Persistent use of opioid needs a medical evaluation and exclusion of chronic post surgical pain. The lack of grading of the evidence of each individual recommendation remains a major weakness of this guidance though evidence quoted for each recommendation have been rigorously reviewed by experts in this field.

Key words:

Surgery, anaesthesia, perioperative, perisurgical, opioids, pain, addiction, guidance.

Introduction:

Opioids are widely used for perioperative analgesia.¹ The post-surgical use of opioids is thought to be an important source of problems particularly in the USA.² The concerns related to opioid use are primarily death due to overdose³ and other morbidity such as addiction and falls. ⁴⁻⁷. There is a 64%increase in all cause mortality (hazard ratio 1.64) in patients who take long term opioids.⁸ Although the opioid misuse problem has not been quantified in the UK, there are concerns that its trajectory mirrors that of the USA.⁹ In England, opioid prescriptions increased by 34% between 1998 and 2016.¹⁰ Prolonged opioid use after surgery is a significant concern as this increases the chances of misuse and opioid related patient safety issues.^{11,12} Persistent post

operative opioid use (PPOU) is the use of opioids 90 days after surgery in preoperative opioid naïve patients. For those on opioids prior to surgery, any increase in baseline opioid use 90 days after surgery would be classed as PPOU. It has been demonstrated that PPOU occurs in 0.6-26% of opioid naïve patients and the figure is 35-77% for those taking opioids prior to surgery.^{12,13}

Concerns surrounding PPOU have led to calls for rational perioperative opioid management¹⁴ and greater display of opioid stewardship by perioperative clinicians that include anaesthesiologists, surgeons, and general practitioners amongst others.^{15,16}

In September 2018, the Faculty of Pain Medicine (FPM) at the Royal College of Anaesthetists (RCOA; London) commissioned a multi professional working party to develop a whole system guidance on the best practice relating to use of opioids perioperatively.¹⁷ The developed guidance is presented here.

80

81 Target population

82 The primary population of interest are all patients who undergo surgery (both major and minor). This include both opioid naïve patients and those taking opioids prior to surgery.

85

86 End users for this guidance

87 This document represents the work of a multi-professional and multidisciplinary collaboration and sets out the guiding principles in opioid management in the perioperative period. This guidance is intended for use by clinicians, nurses and allied

1
2
3 90 healthcare providers, patients, pharmacists and policy makers. Clinicians involved in
4
5 91 perioperative care (Anaesthetists, Surgeons, Pain Nurses, General Practitioners and
6
7 92 Mental health practitioners) may use these guidance to inform their practice on
8
9 93 perioperative opioids. Readers are signposted to the relevant evidence that underpins
10
11 94 this consensus guidance.
12
13
14
15
16
17

18 95
19

20
21 96 Guidance (Practice advisory) development (Methods)
22

23 97 The FPM and the RCOA board laid down the terms of reference for the project working
24
25 98 party in September 2018. The project working party (expert group) was tasked to
26
27 99 develop policy and guidance on opioid prescribing in the perioperative period that was
28
29 100 to include advice on preoperative, intraoperative and postoperative discharge on
30
31 101 opioid management including care transitions from the hospital to primary care.
32
33 102 Additionally, the working group was asked to consider opportunities for opioid de-
34
35 103 escalation of pre- and post-operative opioids and treat chronic post surgical pain.
36
37

38 104 The working party membership and corresponding members included representatives
39
40 105 from the FPM at RCOA, RCGP (Royal College of General Practitioners), RCS (Royal
41
42 106 College of Surgeons, England), BPS (British Pain Society), RCN (Royal College of
43
44 107 Nursing), RCP (Royal College of Psychiatry). A lay person representative from the
45
46 108 RCOA reviewed and commented on the draft consensus statements. The details of
47
48 109 the FPM terms of reference for this guidance may be found at supplementary data 1.
49
50

51
52 110 The mentioned institutions were requested to nominate an ‘expert’ in opioid
53
54 111 prescribing in the perioperative period. The experts involved were individuals with
55
56 112 substantial experience in management, research, teaching or policy analysis of opioid
57
58 113 prescribing in the peri-operative period. The diverse membership of the working party
59
60

1
2
3 114 was intended to have as wide an input as possible to create guidance that was
4
5 115 inclusive of all care transitions or stakeholders for the surgical patient. The expert
6
7 116 group reviewed existing research evidence and clinical practice guidelines prior to
8
9 117 arriving at a consensus. 'Over three years[2018-20] the working group performed a
10
11 118 series of guidance appraisal [Delphi] rounds [four] with the same group of experts. The
12
13 119 first round was a face to face round and the rest were by email. Once a consensus
14
15 120 was reached on all sections of the guidance , the experts took this guidance back to
16
17 121 their respective bodies [partner Institutions RCOA,RCGP,RCS ,RCP,RCN ,BPS
18
19 122 mentioned above] that had nominated them. The partner institutions then fed back
20
21 123 comments to the working group which was discussed amongst the working group and
22
23 124 a consensus reached. Once the final document was finalised, the expert working
24
25 125 group reappraised the document. The lead authors of the working group moderated
26
27 126 the consensus process. Disagreements were resolved using group email discussions
28
29 127 followed till a consensus was reached on a particular issue. The final draft document
30
31 128 then was hosted online on the FPM website for public consultation for a month. We
32
33 129 received feedback from 43 respondents that were discussed by the expert working
34
35 130 group and incorporated to the final guidance.
36
37
38
39
40
41
42

43 131 The rapid review revealed that the evidence base consisted of mostly observational
44
45 132 studies and expert opinion/advisories/guidelines and hence a formal grading of each
46
47 133 recommendation was not performed by the working party for this guidance. Previously
48
49 134 published guidance on allied issues (Buprenorphine) in this journal have reported a
50
51 135 similar evidence base.¹⁸ We have however highlighted the low grade evidence base
52
53 136 (as per Oxford ,UK CEBM Centre for Evidence Based Medicine)¹⁹ available for the
54
55 137 working group's recommendations alongside the headings for each section.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The available evidence was collated, and expert opinion consensus resulted in the development of this whole system pathway for using opioids rationally in the peri-operative period. The guidance development process is shown in Figure 1.

Clinical guidance (Practice advisory)

The detailed recommendations are as follows.

PREOPERATIVE RECOMMENDATIONS (Oxford CEBM¹⁹ Level 2b-5 evidence: cohort studies, case series, expert opinion)

Action: anaesthetists, surgeons, general practitioners, other healthcare professionals

1. Preoperative assessment:

a. Preoperative assessment for complex pain patients should include an assessment of pain and current consumption of analgesic drugs including opioids. Ideally, it should focus on a biopsychosocial assessment of pain as outlined in the FPM guidelines.²⁰⁻²³

2. Prehabilitation:

a. Consideration should be given to reducing preoperative anxiety and catastrophising²⁴, as this may have value in improving post-surgical outcomes including pain.

b. Preoperative counselling must include working collaboratively with the patient²⁵ and expectation management regarding opioid use and perioperative pain management. A patient information leaflet should be provided.

c. Patients with complex pain needs who may benefit from an extended stay in the post anaesthesia care unit (PACU) should be identified, so that appropriate plans can be formulated.

160

161 3. Complex pain cases: (preoperative recommendations for opioid tolerant patients)

162 a. For complex pain patients prescribed high opioid doses, the opinion of a pain
163 specialist²⁵ should be gained prior to surgery.

164 b. A useful way to assess preoperative opioid consumption is through the calculation
165 of the Oral Morphine Equivalent dose (OME)²⁶ which should be documented in the
166 clinical record.

167 c. Opioid tolerance (decrease in pharmacological response) and opioid induced
168 hyperalgesia (increase in pain perception) may occur in patients taking opioids. Opioid
169 tolerance is likely at OME doses 60 mg/day or for ≥ 7 days.²⁷⁻²⁸ Avoid escalating opioid
170 doses before surgery.

171 d. If the oral route is unavailable immediately after surgery, opioid conversion should
172 be made to parenteral morphine.^{26,27}

173 e. Prehabilitation (optimisation before surgery) should include optimal management of
174 preoperative pain and optimisation of opioids and other pain/adjuvant medicines. In
175 selected cases, weaning of opioids should be considered prior to surgery.^{29,30}

176 f. In patients unsuitable for preoperative opioid de-escalation, opioids taken before
177 surgery should usually be continued throughout the surgical admission.

178 g. An individualised plan should be made for patients on buprenorphine (sublingual or
179 transdermal patches) or methadone and in other specific situations such as
180 pregnancy.³¹

181 h. Opioid-sparing adjuncts should be considered when managing pain prior to surgery.

1
2
3 182
4
5
6 183 4. Perioperative management plan:
7
8
9 184 a. A perioperative management plan should be formulated with the patient and
10
11 185 communicated to the surgical and anaesthetic team. The patient should be warned
12
13
14 186 that the plan may occasionally need to be altered.
15

16
17 187
18
19
20 188 Summary of pre-operative recommendations

21
22
23 189 Prehabilitation (optimisation before surgery) should ensure optimal management of
24
25 190 preoperative pain including opioid prescribing, psychological preparation and
26
27 191 education / expectation management. All healthcare professionals involved in
28
29 192 perioperative care should collaborate to provide the highest standards of patient-
30
31 193 centred care including opioid stewardship. Opioids should be used judiciously by
32
33 194 healthcare professionals. This means using opioids when necessary but stopping
34
35 195 opioids when they are no longer required. Patients should be screened for chronic
36
37 196 pain and opioid use in the preoperative period. Opioid weaning should be considered
38
39 197 before surgery if feasible. The Oral Morphine Equivalent (OME) dose per 24 hours of
40
41 198 prescribed opioids should be noted. Referral to a pain specialist should be considered
42
43 199 in complex cases. A perioperative management plan should be formulated with the
44
45 200 patient and communicated to the surgical and anaesthetic team.
46
47
48
49

50
51 201
52
53
54 202 **INTRAOPERATIVE RECOMMENDATIONS (Oxford CEBM¹⁹ Level 2b-5 evidence:**
55
56 203 **cohort studies, case series, expert opinion)**

57
58
59 204 *Action: anaesthetists, surgeons*
60

- 1
2
3 205 1. Intraoperative nociception management as a component of balanced anaesthesia
4
5
6 206 should follow the principles of
7
8
9 207 a. Promotion of early return of usual function, i.e. drinking, eating and mobilisation.³²
10
11
12 208 b. Multimodal analgesia- this has been shown to be opioid sparing and provides
13
14 209 superior pain relief. ³³⁻³⁵
15
16
17 210 c. Opioid sparing analgesia techniques- these and use of opioid sparing adjuvants are
18
19 211 encouraged.³⁶
20
21
22 212 2. PROSPECT (Procedure specific analgesic techniques) recommendations for
23
24 213 analgesia should be used rather than over reliance on the WHO analgesic ladder.³⁷
25
26
27 214 3. Anti-nociception management techniques as a component of a balanced
28
29 215 anaesthesia technique need to be individualised, considering patient choice, type of
30
31
32 216 surgery, comorbidity, and pre-existing medicines. This should be based on shared
33
34 217 decision making with the patient.
35
36
37 218
38
39
40 219 Summary of intraoperative recommendations
41
42
43 220 Intraoperative nociception management as part of a balanced anaesthesia technique
44
45 221 should include multimodal analgesia and opioid-sparing analgesic techniques.
46
47 222 Evidence-based, procedure-specific analgesic techniques should be used when
48
49
50 223 evidence is available. Perioperative antinociception techniques must be tailored to
51
52 224 individual patients. This should be based on shared decision-making, considering the
53
54 225 type of surgery, patient comorbidities and pre-existing medicines use.
55
56
57
58 226
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

227 **POST OPERATIVE RECOMMENDATIONS (Oxford CEBM¹⁹ Level 2b-5 evidence:**
228 **cohort studies, case series, expert opinion)**

229 *Action: anaesthetists, surgeons, other healthcare professionals*

230 Goals:

- 231 1. The goal of postoperative pain management is to minimise postoperative pain and
232 to provide a seamless transition of analgesic care from operating theatre via recovery
233 (PACU) to the ward.
- 234 2. Goals of pain management must be matched to the type of surgery and to the stage
235 of recovery, e.g. after a laparotomy, the immediate goal is the ability to cough and
236 breathe deeply, but in subsequent days it is to facilitate mobilisation.³⁸
- 237 3. Postoperative pain assessment and pain management strategies must promote
238 return of normal function, i.e. drinking, eating, movement and mobilisation.³²

240 **RECOMMENDATIONS FOR POST ANAESTHESIA CARE UNIT (PACU)**

- 241 1. Optimisation of pain relief prior to leaving PACU: Pain assessment in the PACU
242 should take function into account. A pain assessment that involves functional
243 assessment (i.e pain on breathing or movement) along with awareness of factors such
244 as anxiety that can increase pain perception is recommended.
- 245 One example of function-related pain scores is the functional activity score,³⁹ where
- 246 A is no limitation of (relevant) activity due to pain
- 247 B is mild limitation of activity due to pain
- 248 C is being unable to complete activity due to pain.

249

250 2. Managing patients with complex pain problems in recovery:

251 a) Opioid tolerant patients may require additional interventions in PACU to facilitate
252 optimal pain management. These interventions should be planned and documented
253 as far as possible so that a simple reliance on using opioids for pain relief in
254 recovery/PACU is avoided.⁴⁰ In patients with complex pain problems, increased pain
255 intensity taken in isolation should not be a sole indicator to administer further opioids.
256 A comprehensive pain assessment is needed. Repeated elevated pain intensity
257 scores should trigger further assessment and experienced input. Increased pain
258 intensity score should not be a sole indicator for a delay to discharge from PACU. When
259 patients report severe pain, empathy and active listening should be provided.

260

261

262 **RECOMMENDATIONS FOR THE WARD**

263 1. Promote return of normal function:

264 a) The oral route should be used as soon as possible for administration of medicines.

265 b) It must be realised that increased pain intensity may be a consequence of surgical
266 complications (e.g. compartment syndrome or anastomotic leak).

267 c) Sedation scores should be recorded in addition to respiratory rate to detect those
268 at risk of opioid-induced ventilatory impairment.⁴¹⁻⁴⁶

269 2. Immediate-release opioids are preferred in the management of postoperative pain
270 when simple analgesics are insufficient to achieve the analgesic goals. If modified-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

release opioid preparations (including transdermal) are used, due care should be exercised as they have been associated with harm.⁴⁷ The prescribed dose of immediate-release opioids should be age-related (rather than weight) and take into account renal function. Liquid oral morphine at a concentration of 10 mg/5ml is the preferred opioid as it is a Schedule 5 drug in the United Kingdom, which facilitates more timely administration. Immediate-release oxycodone is not recommended as a first-line opioid, as it is a Schedule 2 drug and is more labour intensive to administer. However, it is recognised that in elderly patients aged over 70 years or in patients with renal failure, other opioids may be used post operatively in preference according to local policy.

3. When analgesic requirements are reduced, a reverse analgesic ladder is recommended: wean opioids first, then stop NSAIDs, then stop paracetamol (acetaminophen).

4. The Inpatient Pain Service should be involved in the post-surgical care of the opioid tolerant patient.⁴⁸ Inpatient psychology input may be needed to manage these patients.⁴⁹⁻⁵⁰

5. Patients on gabapentinoids should be identified and the indications reviewed.⁵¹ Gabapentinoids should be tapered if no longer indicated.

DISCHARGE PLANNING

1. Patients should be informed on how to self-administer opioids safely:

293 a. On discharge, patients should be informed how to self-administer opioid medicines
294 safely, wean analgesics and dispose of unused analgesic medicines. Patients should
295 be reminded to take particular care with storing opioids and other medicines that may
296 be liable to misuse. They should be told of the dangers of driving or using machinery
297 while taking opioid medicines, and a patient leaflet should be provided to reinforce
298 these messages.⁵²

299 2. A protocol for discharge medicines should be used as it reduces subsequent opioid
300 use.⁵³⁻⁵⁷ Patients should have access to appropriate simple non-opioid analgesics.

301 a. It is preferable to prescribe opioid and non-opioid analgesics separately in order to
302 allow for dose changes of individual analgesics.

303 b. Patients should be encouraged to keep a record of analgesics taken, as research
304 has shown that this results in better pain control.⁵⁵

305 c. New prescriptions of modified-release opioid preparations (including transdermal
306 patches) should be avoided without specialist consultation. If specialist consultation
307 is required, a key feature of this consult would be to exclude chronic post-surgical pain.

308 3. The hospital discharge letter should be provided in a timely way to all healthcare
309 professionals caring for the patient, including community pharmacists, to avoid an
310 acute prescription of opioids inadvertently becoming a repeat prescription. The
311 hospital discharge letter must explicitly state the recommended opioid dose, amount
312 supplied and planned duration of use. The opioid treatment plan should be agreed
313 with the patient (see MHRA- Medicine and Healthcare regulatory agency guidance on
314 opioids).⁵⁷

315 4. Guidance should be given about medicine review following discharge from hospital:

- 1
2
3 316 a. Usually 5 days and no more than 7 days of opioids (including tramadol) should be
4
5 317 prescribed.⁵⁵
6
7
8 318 b. The hospital discharge letter must explicitly state the recommended opioid
9
10 319 (including tramadol) dose and duration.
11
12
13
14 320
15
16 321 Additional recommendations for opioid tolerant patients
17
18
19 322 5. De-escalation of opioids after pain relieving surgery:
20
21
22 323 a. For opioid-tolerant patients whose surgery was pain relieving, e.g. knee surgery,
23
24 324 the discharge letter should provide advice on any further weaning of analgesics taken
25
26 325 before surgery. Secondary care outpatient pain services or transitional pain services
27
28 326 may be able to assist if difficulties arise.^{58,59}
29
30
31
32
33
34

35 328 **POST DISCHARGE MANAGEMENT**

36
37
38 329 *Action: surgeons, general practitioners, other healthcare professionals*
39
40

- 41 330 1. Patients must be guided and informed to dispose of unused opioid medicines safely
42
43 331 to avoid both diversion and subsequent inappropriate use. Safe disposal must involve
44
45 332 taking excess supplies of medicines to the community or hospital pharmacy.
46
47 333 Postoperative opioids must not be added to a 'repeat' prescribing template. They
48
49 334 should only ever be added to the patient's record as an acute medicine and must be
50
51 335 reviewed at each issue by the prescriber.⁶⁰
52
53
54
55 336 2. If a patient not usually on long term opioids is still taking opioids (including tramadol)
56
57
58 337 90 days after surgery and is still in pain, this should trigger further assessment in
59
60

primary or secondary care which may include referral to a pain service, for investigation of persistent pain following surgery or sometimes to a substance misuse service.⁶¹⁻⁶³

3. Patients on gabapentinoids should be identified and the indications reviewed.⁵¹ Gabapentinoids should be tapered off if no longer indicated.

4. Pain-related and opioid-related readmissions should be notified to the Inpatient Pain team.⁶⁴

For a summary of post-operative recommendations, refer to Figure 2. Pain relief should be optimised before leaving the postoperative recovery area (PACU -post anaesthesia care unit). For patients with complex pain problems, an elevated pain intensity taken in isolation should not be a sole indicator for the administration of further opioids and should not hinder discharge to the ward. A holistic pain assessment is recommended. Postoperative pain assessment and pain management strategies must promote return of normal function, i.e. drinking, eating, movement and mobilisation. Do not treat according to pain intensity but to improve function and mobility. Immediate-release opioids are preferred in the management of postoperative pain (to decrease risk of respiratory impairment and long term continuation), when simple analgesics such as paracetamol (acetaminophen) or NSAIDs are not effective enough to allow the achievement of agreed functional goals. On discharge, patients must be told how to self-administer medicines safely, wean analgesics, and dispose of unused analgesic medicines as well as being told of the dangers of driving while taking medicines. A patient leaflet should be provided to reinforce these messages. Some painful conditions, such as osteoarthritis of the knee, may require surgical procedures

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

to treat pain and improve function. Patients with these conditions may be taking opioid medicines before surgery. These opioids should be gradually withdrawn, where possible, after surgery. Local protocols for the prescription of discharge medicines after surgery should be developed to minimise the chances of subsequent inappropriate opioid use. Ideally this should be managed between the hospital and primary care. The hospital discharge letter must explicitly state the recommended opioid dose, amount supplied and planned duration of use. Guidance should be given about necessary medicine review following discharge from hospital. Usually 5 days and no more than 7 days medication should be prescribed.

Limitations and future directions

This is an expert based consensus guidance (practice advisory) using the best available research on the topic. Though this may be viewed as inferior in the hierarchy of ‘evidence’ due to paucity of high grade evidence, the ‘expert consensus based on evidence’ of an expert panel has been shown to have real world applicability in clinical practice and has served our profession well.^{65,66} Perioperative pain interventions are often ‘complex’ and are made up of a number of active ingredients or components that interact with each other and other factors to bring about an emergent change to outcomes and are considered to have inherent heterogeneity.⁶⁷ The lack of grading of the evidence of each individual recommendation remains a major weakness of this guidance though supporting evidence is quoted for each recommendation and the recommendations and underlying evidence have been rigorously reviewed by experts in this field.

1
2
3 386 This guidance is a pragmatic synthesis of available evidence on this topic presented
4
5 387 in a very practical way. One of the challenges faced was how to handle 'indirect
6
7 388 evidence' or evidence regarding opioid use that had been demonstrated in other health
8
9 389 systems. The experts had to use their judgement in assessing the direction, magnitude
10
11 390 and applicability of the research data prior to applying them within a guidance meant
12
13 391 for the United Kingdom. The panel consensus was reached in a phased, deliberate,
14
15 392 systematic and transparent manner as shown in Figure 1.

16
17
18
19
20 393 For the future, a few questions need to be answered. These are :

21
22
23 394 a] What is the population impact of surgical opioid prescribing on the long term use or
24
25 395 misuse of opioids in the United Kingdom?

26
27
28 396 b] What is the population burden of chronic pain patients taking opioids who require
29
30 397 surgery in the United Kingdom?

31
32
33 398 c] Do chronic pain patients taking opioids presenting for surgery need more healthcare
34
35 399 input, experience more complications, and have poor outcomes?

36
37
38 400 d]What is the best method of prehabilitation for chronic pain patients taking opioids
39
40 401 prior to surgery?

41
42
43 402 e] What is the best time and method of opioid de-escalation prior to and after surgery?

44
45
46 403 f] Does intraoperative opioid use influence long term persistent post surgical pain and
47
48 404 opioid use?

49
50
51
52 405 We understand the heterogeneity of health systems (structure and delivery) worldwide
53
54 406 and outside of the United Kingdom the principles of this guidance should be applied
55
56 407 keeping in mind unique local healthcare system characteristics and resources
57
58 408 available.
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author contribution:

DS and PW were involved in conceptualisation, design, rapid review, forming the working group for the guideline , formulating the structure and content of the document, collection of expert comments, revising the guidance, resolving disagreements and revising/producing the final manuscript.

SH,MR,RB,RK,NL,SC were members of the expert working party for this guideline and contributed content, ideas and critiques for the document and also were involved in the revision /production of the final manuscript.

JH,DL commented and contributed content as external members on this document and were involved in the revision and production of the final manuscript.

DS wrote the manuscript with help from all authors.

All authors approved the manuscript.

Acknowledgements

Thanks are due to Ms Caitlin McAnulty for administrative support at the Faculty of Pain Medicine, London over the two years it took to produce this guideline.

Disclosure of interest

The authors have no conflicts of interest to report

References:

1. Bovill JG, Sebel PS,Stanley T.H. Opioid analgesics in anaesthesia: with special reference to their use in cardiovascular anaesthesia. *Anesthesiology* 1984;**61** (6):731-755.doi.org/10.1097/00000542-198412000-00018.

- 2.Chidgey, B.A., McGinagle, K.L. & McNaull, P.P."When a Vital Sign Leads a Country Astray-The Opioid Epidemic", *JAMA surgery*, 2019; vol. **154**, no. 11: 987-988.doi.org/10.1001/jamasurg.2019.2104.
- 3.Multiple cause of death data. CDC WONDER. Centers for Disease Control and Prevention. Available online at <http://wonder.cdc.gov/mcd.html>. Accessed Nov 29,2020.
- 4.Substance Abuse and Mental Health Services Administration. Results From the 2013 National Survey on Drug Use and Health: Summary of National Findings [NSDUH Series H-48, HHS Publication No. (SMA) 14-4863]. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. Available at <https://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/We b/NSDUHresults2013.pdf>
- 5.Wan Y, Corman S, Gao X, Liu S, Patel H, Mody R. Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain. *Am Health Drug Benefits*. 2015;**8**(2):93-102.doi.org/10.5055/jom.2015.0282.
- 6.Merrill JO, Von Korff M, Banta-Green CJ et al. Prescribed opioid difficulties, depression and opioid dose among chronic opioid therapy patients. *Gen Hosp Psychiatry*. 2012;**34**:581–7.Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665511/pdf/nihms-394083.pdf>
- 7.Morasco BJ, Yarborough BJ, Smith NX et al. Higher prescription opioid dose is associated with worse patient- reported pain outcomes and more health care utilization. *J Pain* 2017;**18**: 437–45. Available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376359/>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

454 8.Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Prescription of Long-Acting
455 Opioids and Mortality in Patients With Chronic Noncancer Pain. *JAMA*.
456 2016;**315**(22):2415-2423. doi:10.1001/jama.2016.7789

457 9.Levy Nicholas, Mills P, Fawcett William J. Avoiding an opioid crisis in the
458 UK *BMJ* 2019; **364** :l1033. doi.org/10.1136/bmj.l1033.

459 10.Curtis, H.J., Croker, R., Walker, A.J., Richards, G.C., Quinlan, J. & Goldacre, B.,
460 "Opioid prescribing trends and geographical variation in England, 1998-2018: a
461 retrospective database study", *The Lancet.Psychiatry* 2019; vol. **6**, no. 2: 140-150.
462 [https://doi.org/10.1016/S2215-0366\(18\)30507-8](https://doi.org/10.1016/S2215-0366(18)30507-8).

463 11.Brummett, C.M., Waljee, J.F., Goesling, J. et al. "New Persistent Opioid Use After
464 Minor and Major Surgical Procedures in US Adults", *JAMA surgery*, 2017;vol. **152**, no.
465 6: pp. e170504.doi.org/10.1001/jamasurg.2017.0504

466 12.Clarke, H., Soneji, N., Ko, D.T. et al., "Rates and risk factors for prolonged opioid
467 use after major surgery: population based cohort study", *BMJ* (Clinical research ed.),
468 2014;vol. **348**: 1251. doi.org/10.1136/bmj.g1251.

469 13.Kent, M.L., Hurley, R.W.& POQI-4 Working Group."American Society for Enhanced
470 Recovery and Perioperative Quality Initiative-4 Joint Consensus Statement on
471 Persistent Postoperative Opioid Use: Definition, Incidence, Risk Factors, and Health
472 Care System Initiatives", *Anesthesia and Analgesia*, 2019; vol. **129**, no. 2: 543-
473 552.doi.org/10.1213/ane.0000000000003941.

474 14.Mohamadi, A., Chan, J.J., Lian, J., Wright et al. "Risk Factors and Pooled Rate of
475 Prolonged Opioid Use Following Trauma or Surgery: A Systematic Review and Meta-
476 (Regression) Analysis", *The Journal of bone and joint surgery.American* volume 2018;
477 vol. **100**, no. 15: 1332-1340. doi.org/10.2106/jbjs.17.01239.

15. Kharasch ED, Avram MJ, Clark JD. Rational Perioperative Opioid Management in the Era of the Opioid Crisis. *Anesthesiology*. 2020;132(4):603-605. doi:10.1097/ALN.0000000000003166
16. Soffin EM, Lee BH, Kumar KK, Wu CL. The prescription opioid crisis: role of the anaesthesiologist in reducing opioid use and misuse. *Br J Anaesth*. 2019;122(6):e198-e208. doi:10.1016/j.bja.2018.11.019
17. **Surgery and Opioids. Best practice 2020. Faculty of Pain Medicine, Royal College of Anaesthesia, London. Available online at - <https://fpm.ac.uk/media/2721> (final document) and https://fpm.ac.uk/sites/fpm/files/documents/2020-09/Surgery-%26-Opioids_version-for-open-consultation-Sep-2020.pdf (public consultation document)**
18. Goel A, Azargive S, Weissman JS, et al. Perioperative Pain and Addiction Interdisciplinary Network (PAIN) clinical practice advisory for perioperative management of buprenorphine: results of a modified Delphi process. *Br J Anaesth*. 2019;123(2):e333-e3. doi.org/10.1136/bmjopen-2018-027374
19. Oxford Centre for Evidence Based Medicine levels of evidence. Available online at : <https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009>
20. Faculty of Pain Medicine. Conducting Quality Consultations in Pain Medicine. 2018. Available online at <https://fpm.ac.uk/media/286>.
21. Perioperative Medicine – The Pathway to Better Surgical Care” Royal College Anaesthetists (2015). Available online at <https://www.rcoa.ac.uk/sites/default/files/documents/201908/Perioperative%20Medicine%20-%20The%20Pathway%20to%20Better%20Care.pdf>

22. Kalkman CJ, Visser K, Moen J et al Preoperative prediction of severe postoperative pain. *Pain* 2003; **105**: 415- 23 3. doi.org/10.1016/s0304-3959(03)00252-5.
23. Janssen K, Kalkman CJ, Grobbee DE et al. The risk of severe postoperative pain: modification and validation of a clinical prediction rule. *Anesth Analg* 2008; **107**:1330-9 . doi.org/10.1213/ane.0b013e31818227da.
- 24.Darnall BD. Pain psychology and pain catastrophizing in the perioperative setting: A review of impacts, interventions, and unmet needs. *Hand Clin* 2016;**32**(1),33-39. doi:10.1016/j.hcl.2015.08.005 [doi]
25. Alter TH, Ilyas AM. A Prospective Randomized Study Analyzing Preoperative Opioid Counseling in Pain Management After Carpal Tunnel Release Surgery. *J Hand Surg Am.* 2017 Oct;42(10):810-815. doi: 10.1016/j.jhsa.2017.07.003. Epub 2017 Sep 8. PMID: 28890331.
26. Faculty of Pain Medicine, PHE. Opioids Aware: Dose equivalents and changing opioids. Available online at <https://fpm.ac.uk/opioids-aware-structured-approach-opioid-prescribing/dose-equivalents-and-changing-opioids>.
- 27.Nielsen S, Degenhardt L., Hoban B, Gisev NA. Synthesis of oral morphine equivalents (OME) for opioid utilisation studies. *Pharmacoepidemiol Drug Saf* 2016;**25**(6):733-737. doi:10.1002/pds.3945 [doi]
- 28.Colvin, L.A., Bull, F. & Hales, T.G. "Perioperative opioid analgesia-when is enough too much? A review of opioid- induced tolerance and hyperalgesia", *Lancet* (London, England), 2019;vol. **393**, no. 10180: 1558-1568. doi.org/10.1016/s0140-6736(19)30430-1.

29. Nguyen LC, Sing DC, Bozic KJ. Preoperative reduction of opioid use before total joint arthroplasty. *J Arthroplasty* 2016; **31**(9 Suppl): 282e7. Available at: <http://dx.doi.org/10.1016/j.arth.2016.01.068>.
30. McAnally, H. Rationale for and approach to preoperative opioid weaning: a preoperative optimization protocol. *Perioper Med* 2017;**6**,19 doi:10.1186/s13741-017-0079-y
31. Quinlan, J. & Cox, F. "Acute pain management in patients with drug dependence syndrome", *Pain reports*, 2017; vol. **2**, no. 4, pp. e611. Available at: <http://dx.doi.org/10.1097/pr9.0000000000000611>.
32. Levy N, Mills P, Mythen M. Is the pursuit of DREAMing (drinking, eating and mobilising) the ultimate goal of anaesthesia? *Anaesthesia* 2016; **71**: 1008–12. Available at: <http://dx.doi.org/10.1111/anae.13495>.
33. Pitchon DN, Dayan AC, Schwenk ES, et al.. Updates on multimodal analgesia for orthopedic surgery. *Anesthesiol Clin* 2018;**36**(3):361-373. doi:S1932-2275(18)30051-X [pii]
34. Memtsoudis SG, Poeran J, Zubizarreta N, et al. Association of multimodal pain management strategies with perioperative outcomes and resource utilization: A population-based study. *Anesthesiol* 2018;**128**(5):891-902. doi:10.1097/ALN.0000000000002132 [doi]
35. Tan M, Law LS, Gan TJ. Optimizing pain management to facilitate enhanced recovery after surgery pathways. *Can J Anaesth* 2015;**62**(2):203-218. doi:10.1007/s12630-014-0275-x [doi]
36. Sultana A, Torres D, Schumann R. Special indications for opioid free anaesthesia and analgesia, patient and procedure related: Including obesity, sleep apnoea, chronic obstructive pulmonary disease, complex regional pain syndromes, opioid addiction

- 549 and cancer surgery. *Best Pract Res Clin Anaesthesiol* 2017;**31**(4):547-560.
550 doi:S1521-6896(17)30082-4 [pii]
- 551 37.PROSPECT Procedure Specific Postoperative Pain Management. Better
552 Postoperative Pain Management. Available online at <http://www.postoppain.org/>
- 553 38.The Joint Commission. R3 Report Issue 11: pain assessment and management
554 standards for hospitals. August 2017. Available from:
555 https://www.jointcommission.org/r3_issue_11/
- 556 39. Halm M, Bailey C, Jeanne MN et al. Pilot Evaluation of a Functional Pain
557 Assessment Scale.*Clinical Nurse Specialist* January/February 2019; Volume 33 -
558 Issue 1 : patient p 12-21 doi: 10.1097/NUR.0000000000000416))
559 435-438.doi.org/10.1016/j.bja.2017.11.098.
- 560 40.Joshi GP, Kehlet H, Beloeil H et al. Guidelines for perioperative pain management:
561 need for re-evaluation. *British Journal of Anaesthesia*. 2017; **119**:703-6. Available at:
562 <http://dx.doi.org/10.1093/bja/aex304>.
- 563 41.Frederickson TW, Gordon D,Pinto M et al. Reducing Adverse Drug Events Related
564 to Opioids Implementation Guide. Philadelphia: *Society of Hospital Medicine*, 2015.
565 Available online at <https://cha.com/wp-content/uploads/2018/01/RADEO.pdf>
- 566 42.Jarzyna D, Jungquist CR, Pasero C et al. American Society for Pain Management
567 Nursing Guidelines on Monitoring for Opioid- Induced Sedation and Respiratory
568 Depression. *Pain Management Nursing: Official Journal of the American Society of*
569 *Pain Management Nurses, American Society for Pain Management Nursing*,
570 2011;**12**(3):118-45.Available at: <http://dx.doi.org/10.1016/j.pmn.2011.06.008>.
- 571 43.Pasero C. Assessment of sedation during opioid administration for pain
572 management.J *Perianesth Nurs*. 2009 Jun; **24**(3): 186–190. doi:
573 10.1016/j.jopan.2009.03.005

- 574 44. Sessler CN, Grap MJ, Ramsay MA. Evaluating and monitoring analgesia and
575 sedation in the intensive care unit. *Crit Care*. 2008;**12** Suppl 3(Suppl 3):S2.
576 doi:10.1186/cc6148
- 577 45. Ramsay MAE, Savage TM, Simpson BRJ, et al: Controlled sedation with
578 alphaxalone. *BMJ* 1974;**2**:656-650. Available at:
579 <http://dx.doi.org/10.1136/bmj.2.5920.656>.
- 580 46. Mascarenhas M, Srivastava D, et al. Using the Model for Improvement to
581 implement the Critical-Care Pain Observation Tool in an adult intensive care unit. *BMJ*
582 *Open Quality* 2018;**7**:e000304. doi: 10.1136/bmjopen-2017-000304
- 583 47. N. Levy, P. Mills. Controlled-release opioids cause harm and should be avoided in
584 management of postoperative pain in opioid naive patients. *British Journal*
585 *of Anaesthesia*, **122** (2019), pp. e86-e90. Available at:
586 <http://dx.doi.org/10.1016/j.bja.2018.09.005>.
- 587 48. Rockett M et al. Guidelines for the Provision of Anaesthesia Services (GPAS).
588 Guidelines for the Provision of Anaesthesia Services for Inpatient Pain Management
589 2019 <https://www.rcoa.ac.uk/system/files/GPAS-2019-11-PAIN.pdf>
- 590 49. Sussman M, Goodier E, Fabri I, et al. Clinical benefits, referral practice and cost
591 implications of an in-hospital pain service: results of a service evaluation in a London
592 teaching hospital. *Br J Pain*. 2017;**11**(1):36-45. doi:10.1177/2049463716673667
- 593 50. Childs SR, Casely EM, Kuehler BM, et al. The clinical psychologist and the
594 management of inpatient pain: a small case series. *Neuropsychiatry Dis Treat*.
595 2014;**10**:2291-2297. Published 2014 Dec 2. doi:10.2147/NDT.S70555
- 596 51. Medicines and Healthcare products Regulatory Agency. 2017. Gabapentin
597 (Neurontin): risk of severe respiratory depression. [https://www.gov.uk/drug-safety-](https://www.gov.uk/drug-safety-update/gabapentin-neurontin-risk-of-severe-respiratory-depression)
598 [update/gabapentin-neurontin-risk-of-severe-respiratory-depression](https://www.gov.uk/drug-safety-update/gabapentin-neurontin-risk-of-severe-respiratory-depression).

1
2
3 599 52.Faculty of Pain Medicine. Opioids Aware resource. Available online at
4
5
6 600 <https://fpm.ac.uk/opioids-aware>
7
8 601 53.Clarke H, Soneji N, Ko, DT, et al. Rates and risk factors for prolonged opioid use
9
10 602 after major surgery: Population based cohort study. *BMJ* 2014;**348**: g1251.
11
12 603 doi:10.1136/bmj.g1251 [doi]
13
14 604 54Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and risk factors for chronic
15
16 605 opioid use among opioid- naive patients in the postoperative period. *JAMA Intern Med*
17
18 606 2016;**176**(9):1286-1293. doi:10.1001/jamainternmed.2016.3298 [doi]
19
20
21 607 55.Brat GA, Agniel D, Beam A., et al. Post surgical prescriptions for opioid naive
22
23 608 patients and association with overdose and misuse: Retrospective cohort study. *BMJ*
24
25 609 2018;**360**:j5790. doi:10.1136/bmj.j5790 [doi]
26
27
28 610 56.Calcatterra SL, Yamashita, TE, Min SJ, Keniston, A, et al. Opioid prescribing at
29
30 611 hospital discharge contributes to chronic opioid use. *J Gen Intern Med* 2016;**31**(5):478-
31
32 612 485. doi:10.1007/s11606-015- 3539-4 [doi]
33
34
35 613 57. MHRA Guidance on Opioids. Sep 2020. Available online at
36
37 614 <https://www.gov.uk/drug-safety-update/opioids-risk-of-dependence-and-addiction>
38
39
40 615 58.Hah JM, Bateman BT, Ratliff J, Curtin C, Sun E. Chronic Opioid Use After Surgery:
41
42 616 Implications for Perioperative Management in the Face of the Opioid Epidemic. *Anesth*
43
44 617 *Analg.* 2017;**125**(5):1733–1740. doi:10.1213/ANE.0000000000002458
45
46
47 618 59.Katz J, Aliza Z. Weinrib, Clarke H. (2019) Chronic postsurgical pain: From risk
48
49 619 factor identification to multidisciplinary management at the Toronto General Hospital
50
51 620 Transitional Pain Service. *Canadian Journal of Pain* **3**:2, pages 49-58.Available at:
52
53 621 <http://dx.doi.org/10.1080/24740527.2019.1574537>.
54
55
56
57
58
59
60

60. Neuman MD, Bateman BT, Wunsch H. Inappropriate opioid prescription after surgery. *Lancet*. 2019 Apr **13**; 393(10180): 1547–1557. doi: 10.1016/S0140-6736(19)30428-3
61. Hill M, et al. Wide Variation and Excessive Dosage of Opioid Prescriptions for Common General Surgical Procedures. *Ann Surg*. 2016 Sep 14. **265**(4), pp.709–714. Available at: <http://dx.doi.org/10.1097/sla.0000000000001993>.
62. Gilron, I., Carr, D. B., Desjardins, P. J., & Kehlet, H. (2018). Current methods and challenges for acute pain clinical trials. *Pain reports*, **4**(3), e647. doi:10.1097/PR9.0000000000000647.
63. Hemmings, H C. & Lambert, D.G., 2019. The good, the bad, and the ugly: the many faces of opioids. *British Journal of Anaesthesia*, Volume 122, Issue **6**, 705 – 707. Available at: <http://dx.doi.org/10.1016/j.bja.2019.04.003>.
64. Levy, N et al. Post-surgical pain management: time for a paradigm shift. *British Journal of Anaesthesia*, Vol **123**, Issue 2, e182-6. Available at: <http://dx.doi.org/10.1016/j.bja.2019.05.031>.
65. Eibling D, Fried M, Blitzer A, Postma G. Commentary on the role of expert opinion in developing evidence-based guidelines. *Laryngoscope*. 2014;**124**(2):355-357. doi:10.1002/lary.24175
66. Schünemann HJ, Zhang Y, Oxman AD. Distinguishing opinion from evidence in guidelines *BMJ* 2019; **366** :l4606. Available at: <http://dx.doi.org/10.1136/bmj.l4606>.
67. Masterson-Algar, P., Burton, C.R. & Rycroft-Malone, J. The generation of consensus guidelines for carrying out process evaluations in rehabilitation research. *BMC Med Res Methodol* **18**, 180 (2018). <https://doi.org/10.1186/s12874-018-0647-y>